| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Corcept accused in California for stifling Teva's generic launch | 31 | Seeking Alpha | ||
| Do | Teva Pharmaceutical Industries Ltd: Putting Patients First: Why Europe Must Act to Protect Access To Medicines | 259 | GlobeNewswire (Europe) | AMSTERDAM, Feb. 20, 2025 (GLOBE NEWSWIRE) -- New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider.... ► Artikel lesen | |
| Di | Teva Pharmaceutical Industries Ltd: Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) | 292 | GlobeNewswire (Europe) | TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on... ► Artikel lesen | |
| Di | FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea | 24 | Investopedia | ||
| Di | Teva and Alvotech gets FDA review acceptance for its proposed biosimilar to Eylea | 13 | Seeking Alpha | ||
| Di | Teva Pharmaceutical Industries Ltd; Alvotech: Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept) | 342 | GlobeNewswire (Europe) | REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for... ► Artikel lesen | |
| Mo | Teva CEO responds to 25% share price fall | 90 | Globes | ||
| 14.02. | Teva EVP Mark Sabag verkauft Aktien im Wert von 2,89 Millionen US-Dollar | 81 | Investing.com Deutsch | ||
| 11.02. | Axsome Stock Surges 20% on Auvelity Patent Settlement With Teva | 30 | Zacks | ||
| 11.02. | Axsome stock target raised to $190 on Teva litigation resolution | 24 | Investing.com | ||
| 10.02. | Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity | 29 | Benzinga.com | ||
| 10.02. | Axsome secures top drug's future with Teva patent settlement | 16 | BioPharma Dive | ||
| 10.02. | Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' | 8 | Benzinga.com | ||
| 10.02. | Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038 | 22 | FiercePharma | ||
| 10.02. | Axsome settles Auvelity patent litigation with Teva | 23 | Seeking Alpha | ||
| 10.02. | Axsome Therapeutics Reaches Settlement With Teva On AUVELITY Patent Litigation | 16 | RTTNews | ||
| 10.02. | Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia | 33 | Seeking Alpha | ||
| 10.02. | Medincell: Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals | 299 | Business Wire | Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit) Richard Malamut, Chief Medical Officer at Medincell comments:... ► Artikel lesen | |
| 09.02. | Teva files to raise first capital since 2016 | 41 | Globes | ||
| 09.02. | Sun: TASE down as Teva declines continue | 13 | Globes |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| RHEINMETALL | 2.254 |
| BYD | 2.246 |
| SUPER MICRO COMPUTER | 2.094 |
| RENK GROUP | 1.941 |
| TUI | 1.914 |
| PALANTIR TECHNOLOGIES | 1.798 |
| MERCEDES-BENZ | 1.782 |
| ALIBABA | 1.768 |
| NVIDIA | 1.538 |
| BAYER | 1.386 |
| VARTA | 1.238 |
| THYSSENKRUPP | 1.158 |
| D-WAVE QUANTUM | 1.119 |
| EVOTEC | 1.110 |
| TESLA | 1.029 |
| XIAOMI | 780 |
| NEL | 740 |
| INTEL | 730 |
| NEWMONT | 703 |
| PUMA | 689 |
| BITCOIN GROUP SE | 659 |
| COMMERZBANK | 659 |
| BARRICK GOLD | 644 |
| INFINEON | 635 |
| DEUTSCHE BANK | 618 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
